Phase 3 trial of RVX000222 for prevention of major cardiovascular events in high-risk adults with type 2 diabetes and coronary artery disease

Phase 3, randomised, double-blind trial in cardiac morbidity, coronary arteriosclerosis and type 2 diabetes mellitus (T2DM) comparing RVX000222 plus intensive statin therapy with Placebo plus intensive statin therapy (2 arms). Primary endpoint: Time to major adverse cardiovascular events. Started Sep 2015; status: recruiting.